NEO (NEO) revenue breakdown
By segment, Clinical Services is the largest at 84% of fiscal 2023 revenue; Advanced Diagnostics grew fastest, 24% a year over 7 years.
By product, Client direct billing is the largest at 71% of fiscal 2025 revenue; Commercial insurance grew fastest, 17% a year over 3 years.
Revenue by segment
Fiscal years, as NEO reports them in its 10-K filings; fiscal 2023 total $592M.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Clinical Services | $210M | $213M | $242M | $361M | $382M | $404M | $419M | $496M | 84% |
| Advanced Diagnostics | $22M | $27M | $35M | $48M | $62M | $80M | $91M | $96M | 16% |
Revenue by product
Fiscal years, as NEO reports them in its 10-K filings; fiscal 2025 total $727M.
| Products | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| Client direct billing | $371M | $429M | $475M | $519M | 71% |
| Commercial insurance | $73M | $88M | $100M | $118M | 16% |
| Medicare and other government | $66M | $74M | $85M | $91M | 12% |
| Self-pay | $157,000 | $350,000 | $681,000 | $114,000 | 0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for NEO.
Open NEO in InvestinglyQuestions
Where does NEO make its money?
In fiscal 2023, by segment: Clinical Services $496M, Advanced Diagnostics $96M.
From NEO's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.